INTERCEPT is not approved for sale in the United States and certain other countries.

SIGN UP FOR OUR
E-NEWSLETTER

INTERCEPT eNews delivers product news & information updates.

INTERCEPT eNews Archive

INTERCEPT eNews Features

 

  • Product updates and announcements
     
  • Events, webinars and congresses
     
  • INTERCEPT in the news
     
  • INTERCEPT customer profiles
     
  • Industry news and events
     
  • Highlights of Industry publications
     
  • Pathogen spotlight
     

enews


PAST ISSUES 

2014

February - Evidence Highlights Clinical and Cost Benefits of Platelet Additive Solution
January
- ESA Guidelines for Management of Severe Perioperative Bleeding Recommend INTERCEPT for Platelets

2013

December - Cerus Submits Final PMA Module for INTERCEPT Plasma to FDA
October - Cerus Submits First of Three PMA Modules to FDA for INTERCEPT Platelets
September - Blood Collections Suspended in Florida, USA due to Dengue Outbreak
August  - Probable WNV Transfusion-Transmitted Infection Results in Fatality
July
- Cerus Initiates Two European Phase III Clinical Trials for INTERCEPT RBCs
May - US FDA Agrees to Cerus' Proposed Modular PMA Shell for INTERCEPT Platelets
April - Swiss HV Data Show Favourable Safety Profile for INTERCEPT-treated Platelet Components
March - US FDA accepts request to file PMA for INTERCEPT Platelets
February - FDA Agrees to Cerus' Proposed Modular PMA Shell for INTERCEPT Plasma

2012

December - Cerus Signs Agreement with 2 Swiss Centers for Implementation of INTERCEPT Plasma
November - Cerus to Seek INTERCEPT Plasma Approval in the U.S.
October - Cerus Partners with American Red Cross and Blood Systems for INTERCEPT Plasma for TTP
September - Leading Medical Center in Turkey Adopts INTERCEPT Blood System
August- Maximum Platelet Input Extended for INTERCEPT DS Set
July
- INTERCEPT Adoption Expands into Latin America
May
- Cerus Announces Collaboration to Develop Whole Blood Pathogen Inactivation System for Africa
April - General Hospital of Vienna Implements INTERCEPT Platelets in Routine Use
March - IDE Supplement for Phase III Trial of INTERCEPT Red Blood Cells Submitted to FDA
February - INTERCEPT Platelets and Plasma Gain Approvals in Israel

2011

December - INTERCEPT Chosen for Illuminator Contracts in Russia
November - Cerus Awarded New Supply Agreement with French National Blood Service
October
- France : Afssaps to Replace Methylene Blue with INTERCEPT and SD Plasma
September
- Swiss Publication Reports on Safety, Efficacy, and Economics of Double Dose INTERCEPT Platelets
August
- 2010 Dengue Outbreak Resulted in Significant Loss of Australian Blood Supply
July
- Child's Death Linked to Bacterial Contamination in Transfused Platelets
June
- E.coli Outbreak Puts Spotlight on Blood Availability
May
- German Publication Confirms Efficacy of INTERCEPT Platelets
April - TESSI Study Published in the British Journal of Haematology
March - First German Center Begins Routine use of INTERCEPT Plasma
February - TSR.ch interviews Swiss Red Cross in Lausanne regarding INTERCEPT Platelets

Please Note: Archived eNews publications are not updated; therefore, information contained in the archived material may be out of date or no longer valid.

 

Untitled Document